Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1189 in Respiratory Insufficiency Caused by Respiratory Viral Infection
NCT07633288Phase 2Recruiting
- Sponsor
- SynAct Pharma AB
- Start
- May 2026
- Primary completion
- Aug 2027
- Countries
- 4
01
Overview
A Phase 2 trial of resomelagon in respiratory viral infection, Respiratory Insufficiency (RI), sponsored by SynAct Pharma AB. Started May 2026; status: recruiting.
02
Drugs
resomelagon
03
Conditions
respiratory viral infectionRespiratory Insufficiency (RI)
Beyond the preview
Go deeper on NCT07633288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07633288.